A Phase 4 interventional study of Atorvastatin and Atorvastatin in Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-12.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 49th largest by enrollment of the 75 interventional ones that give a count, is one of 13 that started in 2008, is one of 28 in phase 4, and was the 38th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 13 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 75 interventional studies. Of the 69 that completed or were terminated, 33 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 77 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
19 studies in Hypercholesterolemia by Viatris Inc.: none open now, none under way, none of them phase 3. Of 19 finished, 10 (53%) have results posted.
Among the 19 studies in Hypercholesterolemia by Viatris Inc., this one is the 11th largest by enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2008, is one of 8 in phase 4, and was the 13th registered.
Viatris Inc.’s Hypercholesterolemia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, from their registry updates:
Among Viatris Inc.’s 19 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mg atorvastatin
Drug: Atorvastatin
New 10 mg atorvastatin tablet
Drug: Atorvastatin
A single 10 mg dose of marketed 10 mg atorvastatin tablets
A single 10 mg dose of new formulation of 10 mg atorvastatin
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Infinity)
AUCinf = Area under the plasma concentration-time curve from time 0 (predose) extrapolated to infinite time; measured in nanograms times hour per milliliter (ng•hr/mL).
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 10, 12, 24, 36, 48, 72 hours post dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
AUClast = area under the plasma concentration-time curve from 0 (predose) to the time of the last measureable concentration (Clast); measured in nanograms times hour per milliliter (ng•hr/mL).
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 10, 12, 24, 36, 48, 72 hours post dose
Maximum Observed Plasma Concentration (Cmax)
Cmax = maximum observed plasma concentration. Measured in nanograms per milliter (ng/mL).
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 10, 12, 24, 36, 48, 72 hours post dose
Time to Reach Maximum Plasma Concentration (Tmax)
Tmax = time (hours) to maximum plasma concentration (Cmax).
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 10, 12, 24, 36, 48, 72 hours post dose
Plasma Elimination Half-life (t1/2)
t1/2 = terminal elimination half-life in hours.
Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 10, 12, 24, 36, 48, 72 hours post dose
Healthy volunteers were recruited from one research center between July 2008 and September 2008.
| Milestone | Test Drug First, Then Reference Drug | Reference Drug First, Then Test Drug |
|---|---|---|
| Started | 39 | 37 |
| Completed | 39 | 37 |
| Not completed | 0 | 0 |
| Milestone | Test Drug First, Then Reference Drug | Reference Drug First, Then Test Drug |
|---|---|---|
| Started | 39 | 37 |
| Completed | 37 | 37 |
| Not completed | 2 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | Test Drug First, Then Reference Drug | Reference Drug First, Then Test Drug |
|---|---|---|
| Started | 37 | 37 |
| Completed | 37 | 37 |
| Not completed | 0 | 0 |
AUCinf = Area under the plasma concentration-time curve from time 0 (predose) extrapolated to infinite time; measured in nanograms times hour per milliliter (ng•hr/mL).
| ng•hr/mL | Test Drug | Reference Drug |
|---|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Infinity) | 18.3206 ± 8.26454 | 19.2583 ± 8.79739 |
AUClast = area under the plasma concentration-time curve from 0 (predose) to the time of the last measureable concentration (Clast); measured in nanograms times hour per milliliter (ng•hr/mL).
| ng•hr/mL | Test Drug | Reference Drug |
|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) | 15.7382 ± 7.88920 | 16.5452 ± 8.71551 |
Cmax = maximum observed plasma concentration. Measured in nanograms per milliter (ng/mL).
| ng/mL | Test Drug | Reference Drug |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 2.6594 ± 1.44617 | 2.8086 ± 1.23048 |
Tmax = time (hours) to maximum plasma concentration (Cmax).
| hours | Test Drug | Reference Drug |
|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) | 1.000 (0.250 to 9.000) | 0.5000 (0.250 to 4.000) |
t1/2 = terminal elimination half-life in hours.
| hours | Test Drug | Reference Drug |
|---|---|---|
| Plasma Elimination Half-life (t1/2) | 10.39 ± 4.0018 | 10.78 ± 3.9640 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test Drug | — | — | — |
| Reference Drug | — | — | — |
| Event | Test Drug | Reference Drug |
|---|---|---|
| Renal colicRenal and urinary disorders | 1/76 | 0/74 |
| Event | Test Drug | Reference Drug |
|---|---|---|
| HeadacheNervous system disorders | 1/76 | 6/74 |
| ConstipationGastrointestinal disorders | 1/76 | 4/74 |
| NauseaGastrointestinal disorders | 0/76 | 2/74 |
| Syncope vasovagalNervous system disorders | 0/76 | 2/74 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 0/76 | 2/74 |
| DyspepsiaGastrointestinal disorders | 0/76 | 1/74 |
| VomitingGastrointestinal disorders | 0/76 | 1/74 |
| DizzinessNervous system disorders | 1/76 | 1/74 |
| SyncopeNervous system disorders | 0/76 | 1/74 |
| AnxietyPsychiatric disorders | 0/76 | 1/74 |
| Age, Customized(participants) | Total Number of Participants |
|---|---|
| 18-44 years | 59 |
| 45-64 years | 17 |
| Sex: Female, Male(Participants) | Total Number of Participants |
|---|---|
| Female | 38 |
| Male | 38 |
The record gives a start of Jul 2008, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →